Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
Background and rationale for guideline development: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the spine and sacroiliac joints [1]. It can also involve peripheral joints and entheses, and extra-musculoskeletal manifestations (EMMs) such as acute anterior uveitis, psoriasis and IBD. Since the previous version of the British Society for Rheumatology (BSR) axSpA guideline [2], which only included TNF inhibitors, pharmacological treatment options and strategies for axSpA have expanded, alongside rapid advancements in the treatment of EMMs as index conditions. In this increasingly complex and evolving therapeutic landscape, we aimed to update the guideline for health professionals in the UK who care for adults with axSpA.
Authors
- Ben Thompson (ORCID: https://orcid.org/0000-0002-0481-279X)
- Kalveer Flora
- Max M. Yates (ORCID: https://orcid.org/0000-0003-3977-8920)
- Christopher A Lamb (ORCID: https://orcid.org/0000-0002-7271-4956)
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- Daniëlle van der Windt (ORCID: https://orcid.org/0000-0002-7248-6703)
- Lambert Felix
- Antoni Chan (ORCID: https://orcid.org/0000-0003-2323-8161)
- Joe Eddison
- Sizheng Steven Zhao (ORCID: https://orcid.org/0000-0002-3558-7353)
- Karl Gaffney (ORCID: https://orcid.org/0000-0002-7863-9176)
- Daniel J. Murphy (ORCID: https://orcid.org/0000-0003-0927-8386)
- Stephanie R Harrison (ORCID: https://orcid.org/0000-0002-7465-2621)
- Raj Sengupta (ORCID: https://orcid.org/0000-0002-9720-0396)
- Helena Marzo‐Ortega (ORCID: https://orcid.org/0000-0002-9683-3407)
- Stefan Siebert (ORCID: https://orcid.org/0000-0002-1802-7311)
- Gareth T. Jones (ORCID: https://orcid.org/0000-0003-0016-7591)
- Harry Petrushkin (ORCID: https://orcid.org/0000-0002-4662-2994)
- Nick Clarke (ORCID: https://orcid.org/0000-0001-8666-5449)
- William J Gregory (ORCID: https://orcid.org/0000-0002-1186-5806)
- Charlotte Davis
- Virinderjit Sandhu
- Dale Webb
Institutions
- University of East Anglia (GB)
- Manchester Metropolitan University (GB)
- Royal National Hospital for Rheumatic Diseases (GB)
- University of Leeds (GB)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Aberdeen (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Manchester Academic Health Science Centre (GB)
- Norfolk and Norwich University Hospitals NHS Foundation Trust (GB)
- London North West Healthcare NHS Trust (GB)
- Royal United Hospital (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- Royal Devon and Exeter Hospital (GB)
- Royal Berkshire NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Manchester (GB)
- Clinical Research Institute (US)
- Arthritis Society (CA)
- Manchester University NHS Foundation Trust (GB)
- Salford Royal Hospital (GB)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Arthritis UK (GB)
- Expert System (Italy) (IT)
- NIHR Manchester Biomedical Research Centre (GB)
- Keele University (GB)
- University of Glasgow (GB)
- Newcastle University (GB)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1093/rheumatology/keaf090
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Manchester Biomedical Research Centre